ANZCTR search results

This study aims to investigate whether a safe, non-invasive form of brain stimulation delivered at home can improve attention in children and young people aged 8–24 years following an acquired brain injury. Participants will be randomly assigned to receive one of two types of brain stimulation or a sham (placebo) stimulation while completing a computer-based attention training activity for 20 minutes a day over 10 weekdays. The first and last sessions will take place at the research centre, while the remaining sessions will be completed at home under video-call supervision from the research team. Participants will also complete assessments of attention, hand function, and brain activity before and after the intervention, as well as one week later to determine whether any effects are maintained. We hypothesise that active brain stimulation combined with attention training will lead to greater improvements in attention compared with sham stimulation. The findings from this study may help inform the development of safe and accessible therapies to support cognitive recovery following childhood-acquired brain injury.

This is a pilot randomised controlled trial study. Twenty participants with a clinical or imaging-based diagnosis of endometriosis who are scheduled for laparoscopic excision surgery will receive a pre-operative course of home-based tDCS (active or sham). The primary purpose is to assess feasibility metrics and obtain preliminary effect size estimates to power a subsequent randomised controlled trial.

Guided by the RE-AIM framework, this multi-phase implementation study translates CIRCuiTS into routine mental health practice and examines the reach, adoption, implementation, effectiveness, and sustainability of the CIRCuiTS cognitive remediation therapy program for people with psychosis across four Australian public mental health services.

There are many models of maternity care available in Victoria. The model of care during pregnancy and the model of care at the onset of labour/admission to hospital for the birth is reported to the Victorian Perinatal Data Collection for all births This project will use this population-based dataset to analyse: -characteristics of women using the various models of care (e.g. residential location, age group, Aboriginal status, complexity of their pregnancy); -variation between models of care in the nature of the care provided (e.g. number of visits, maternal vaccinations in pregnancy); -differences in intrapartum care; -outcomes of the various models for women and for babies (e.g. mode of birth, maternal and neonatal complications, early infant feeding). All other models will be compared with private obstetric care.

This study will test whether a conservative treatment called full coronal pulpotomy can successfully save painful, deeply decayed adult teeth, even when some bleeding from the nerve tissue is deliberately allowed to continue before sealing the tooth. In this procedure, the dentist removes the inflamed nerve tissue from the crown of the tooth, places a modern bioactive cement over the remaining healthy pulp, and restores the tooth with a permanent filling, then reviews patients at 6 and 12 months to check pain levels, tooth function, and X-ray healing. The purpose is to see if this approach provides tooth survival and symptom relief that are not worse than those reported for conventional vital pulp therapy and standard root canal treatment, within a preplanned 10% margin. The study hypothesis is that allowing intentional uncontrolled bleeding (intentional uncontrolled haemostasis) during full coronal pulpotomy in these teeth will not lead to inferior 6 months or 12-month clinical and radiographic outcomes compared with published results for conventional vital pulp therapy and nonsurgical root canal treatment.

Gout is a painful form of arthritis caused by urate crystal deposition and is common in people with kidney failure receiving haemodialysis. Allopurinol is routinely prescribed to lower urate levels and prevent flares. However, haemodialysis itself removes urate, raising the possibility that some patients may no longer require allopurinol.. This pilot study will evaluate whether gradually stopping allopurinol is safe, effective, and feasible in haemodialysis patients with well-controlled gout. Participants will undergo stepwise dose reduction with regular blood tests and receive medication to prevent gout flares during the process. If a flare occurs, dose reduction will be stopped and usual treatment resumed. The study aims to reduce medication burden in this population and inform the design of a larger clinical trial and future clinical guidelines.

The PROTECT-PD Study is a randomised, double-blind, placebo-controlled study designed to assess the efficacy, safety and tolerability of Probucol (Lorelco™) in individuals with early to moderate Parkinson’s disease (PD). The trial will investigate whether Probucol can slow disease progression while maintaining an acceptable safety profile in approximately 140 participants. If you are eligible and choose to take part, you will be randomly assigned to receive either Probucol (Lorelco™) or a placebo (an inactive capsule). You will take two capsules each day, one in the morning and one at night. Your participation will last up to 82 weeks (about 19 months), including up to 8 weeks of screening, 78 weeks of treatment, and a 4-week follow-up after treatment ends.

The SIC PIN trial aims to evaluate the use of the Sirius Pintuition marker clip for non-palpable breast lesions in breast cancer diagnosis and surgery. Who is it for? You may be eligible for this trial if you are an adult female, non-lactating and have a impalpable breast lesion. Study details Participants will have the marker clips inserted by subspecialist breast Radiologists adjacent to non-palpable breast tumours. They will then go on to have surgical excision of these tumours. It is hoped that findings from this study will help inform researchers as to the utility and feasibility of the Sirius Pintuition marker clip in breast cancer diagnosis and surgery.

The present study aim is to evaluate the tolerability and feasibility of repeat LIFU treatments in participants with AD using a bespoke low frequency transcranial LIFU investigational device termed Ceretas Device. To evaluate the efficacy of the Ceretas device on the overall neuropsychiatric symptom burden in probable Alzheimer patients.

The EVADE-1 study aims to assess whether a new cancer treatment, evexomostat, shows signs of anti-cancer activity in patients with advanced prostate cancer that has spread to other tissues, and to better understand the safety and tolerability of this treatment in patients with advanced prostate cancer. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with metastatic castration-resistant prostate cancer and your cancer deposits/tumours also show low uptake on PSMA PET scans and/or increased uptake on FDG PET scans. You may need to ask your doctor to confirm whether your cancer meets these requirements. Study details All participants who choose to enrol in this study will be asked to attend the Princess Alexandra Hospital, Brisbane once per fortnight to receive an injection under the skin of evexomostat. If participants don't experience any severe side effects while receiving evexomostat, they will be able to continue attending fortnightly for up to 24 weeks (12 doses). Throughout the study, all participants will be asked to undergo additional PET/CT scans (4 in total), blood tests and clinical assessments to monitor their safety and any response to the treatment. It is hoped this research will determine whether regular doses of evexomostat are safe and tolerated by patients with advanced prostate cancer and to determine the effect of evexomostat on cancer activity. If the study finds that this treatment is safe and has an anti-cancer effect, a larger study to assess the treatment in a greater number of patients with advanced prostate cancer may be undertaken.